Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03598608
Title Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.

non-Hodgkin lymphoma

diffuse large B-cell lymphoma

Hodgkin's lymphoma


MK-4280 + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | ITA | DEU | CAN

No variant requirements are available.